China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
18 Junio 2024 - 5:27AM
- Innovative drug Methylthioninium Chloride Enteric-coated
Sustained-release Tablets (Lumeblue®) is an oral diagnostic drug,
approved by China’s NMPA for enhancing visualisation of colorectal
lesions in adult patients undergoing screening or surveillance
colonoscopy.
- The results of the Phase III clinical trial in China show that
the Product can significantly improve the detection rate of
non-polypoid colorectal lesions (the primary endpoint of the
study), leading to an improved detection rate of dangerous lesions
such as non-polypoid adenomas (the secondary endpoint).
- The Product can be taken during the bowel preparation step,
ensuring that colorectal staining is completed by the time
colonoscopy is conducted. This not only enhances the detection rate
of colorectal lesions but also potentially simplifies the
colonoscopy procedure, making the examination more efficient and
improving the screening benefits.
- As of now, CMS's newly launched innovative portfolio has been
expanded to 5 products, continuously generating driving force to
the Group’s sustainable and healthy development.
China Medical System Holdings Limited (the
“Company”, together with its subsidiaries, the “Group” or “CMS”) is
pleased to announce that on 11 June 2024, the New Drug Application
(NDA) of the Group’s innovative drug methylthioninium chloride
enteric-coated sustained-release tablets (Lumeblue®) (the
“Product”) has been approved by the National Medical Products
Administration of China (NMPA). The drug registration certificate
was obtained on 18 June 2024. The Product is indicated to enhancing
visualisation of colorectal lesions in adult patients undergoing
screening or surveillance colonoscopy, and it is the first oral
methylthioninium chloride enteric-coated sustained-release tablets
in China. The Group will synergize with existing gastroenterology
products and resources to advance the commercialization and
academic promotion related works of the Product in an orderly
manner, aiming to achieve nationwide large-scale clinical
application as soon as possible so as to benefit patients with
colorectal disease.
Lumeblue® is an oral diagnostic drug that uses
patented multi-matrix (MMX) technology to deliver active substances
directly to the colon and release them locally in a controlled
manner. As an enhancer dye, the Product increases the contrast
between colorectal lesions and healthy mucosa. The results of the
Phase III clinical trial in China show that the Product can
significantly improve the detection rate of non-polypoid colorectal
lesions (the primary endpoint of the study), leading to an improved
detection rate of dangerous lesions such as non-polypoid adenomas
(the secondary endpoint)[1]. In addition, the Product can be taken
during the bowel preparation step, ensuring that colorectal
staining is completed by the time colonoscopy is conducted. This
not only enhances the detection rate of colorectal lesions but also
potentially simplifies the colonoscopy procedure, making the
examination more efficient and improving the screening
benefits.
According to the diagnosis and treatment data of
the Digestive Endoscopy Branch of the Chinese Medical Association,
approximately a total of 28 million gastroenteroscopies were
completed nationwide in 2012, including 5.83 million colonoscopies.
In 2019, approximately 38.73 million gastroenteroscopies were
completed nationwide, an increase of 34.62% compared with 2012[2].
The Chinese consensus of early colorectal cancer screening
recommends that people aged 50 to 75 years old should be screened
for colorectal cancer regardless of whether they have alarm
symptoms[3]. There are approximately 400 million people aged 50 to
75 in China in 2020[4]. With the popularity of early screening for
colorectal cancer in China, it is expected to witness a
considerable growth of the number of colonoscopies in China in the
future.
The Product has been approved by the European
Medicines Agency (EMA) to be commercialized in the European Union
under the trade name Lumeblue™ in August 2020. The Group obtained
an exclusive license for the Product from Cosmo Technologies Ltd, a
fully owned subsidiary of Cosmo Pharmaceuticals NV, on 3 December
2020.
Driven by the twin-wheel of "Collaborative
R&D and Independent R&D", CMS has continuously deployed
global first-in-class (FIC) and best-in-class (BIC) innovative
products guided by patient and clinical demands. With enhancing
R&D capabilities in developing differentiated innovative
products, CMS has empowered the continuous transformation of
scientific research outcomes into clinical application,
continuously releasing the value of innovation. As of now, CMS's
newly launched innovative portfolio has been expanded to 5
products, continuously generating driving force to the Group’s
sustainable and healthy development. Desidustat Tablets and
Methotrexate Injection (rheumatoid arthritis), CMS’s innovative
pipeline products, are currently under NDA review in China.
Meanwhile, over 10 innovative pipeline products are undergoing
clinical trials in China, mainly randomized controlled trials
(RCT). CMS is expected to launch differentiated innovative products
every year in the future with higher efficiency and more
controllable costs, continuing to optimize its product portfolio
and build fresh driving forces for the mid- to long-term
development of the Company.
About CMSCMS is a platform company
linking pharmaceutical innovation and commercialization with strong
product lifecycle management capability, dedicated to providing
competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC)
and best-in-class (BIC) innovative products, and efficiently
promotes the clinical research, development and commercialization
of innovative products, enabling the continuous transformation of
scientific research into clinical practices to benefit
patients.
CMS deeply engages in several specialty
therapeutic fields, and has developed proven commercialization
capabilities, extensive networks and expert resources, resulting in
leading academic and market positions for its major marketed
products. CMS continues to promote the in-depth development of its
advantageous specialty fields and expand business boundaries. While
strengthening the competitiveness of the
cardio-cerebrovascular/gastroenterology business, CMS independently
operates its dermatology and medical aesthetics business, and
ophthalmology business, aiming to gain leading positions in
specialty therapeutic fields, whilst enhancing the scale and
efficiency. At the same time, CMS has expanded its business
territory to the Southeast Asian market, striving to become a
"bridgehead" for global pharmaceutical companies to enter the
Southeast Asian market, further escorting the sustainable and
healthy development of the Group.
Reference:
- The results of the Phase III clinical trial in China was
published and can be found at:
https://web.cms.net.cn/en/2022/12/positive-results-for-china-phase-iii-clinical-trial-of-methylthioninium-chloride-enteric-coated-sustained-release-tablets/
- The diagnosis and treatment data of the Digestive Endoscopy
Branch of the Chinese Medical Association
- Chinese consensus of early colorectal cancer screening (2019,
Shanghai),Chinese Journal of Internal Medicine,DOI:
10.3760/cma.j.issn.0578-1426.2019.10.004
- CHINA POPULATION CENSUS YEARBOOK 2020, can be found at:
https://www.stats.gov.cn/sj/pcsj/rkpc/7rp/zk/indexch.htm
CMS Disclaimer and Forward-Looking
StatementsThis press release is not intended to promote any
products to you and is not for advertising purposes. This press
release does not recommend any drugs, medical devices and/or
indications. If you want to know more about the diagnosis and
treatment of specific diseases, please follow the opinions or
guidance of your doctor or other medical and health professionals.
Any treatment-related decisions made by healthcare professionals
should be based on the patient’s specific circumstances and in
accordance with the drug package insert.
This press release which has been prepared by
CMS does not constitute any offer or invitation to purchase or
subscribe for any securities, and shall not form the basis for or
be relied on in connection with any contract or binding commitment
whatsoever. This press release has been prepared by CMS based on
information and data which it considers reliable, but CMS makes no
representation or warranty, express or implied, whatsoever, and no
reliance shall be placed on, the truth, accuracy, completeness,
fairness and reasonableness of the contents of this press release.
Certain matters discussed in this press release may contain
statements regarding the Group’s market opportunity and business
prospects that are individually and collectively forward-looking
statements. Such forward-looking statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties and assumptions that are difficult to predict. Any
forward-looking statements and projections made by third parties
included in this press release are not adopted by the Group and the
Company is not responsible for such third-party statements and
projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
Source: China Medical System Holdings Ltd.